Tag Archives: MedRxiv

medRxiv – Preprint Server for Health Sciences

Posted on by

First launched only about a year and a half ago in June 2019, preprint server medRxiv has enjoyed a super-sharp uptick in the number of manuscripts posted since February 2020, largely due to COVID-19 related submissions. medRxiv is not a journal publication or journal publisher – rather it is a preprint server or outlet for “the distribution of preprints that are complete but unpublished manuscripts describing health research”.

The pandemic has certainly put preprints on the fast-track to acceptance by the clinical research community, despite the fact that they are “preliminary reports of work that have not been certified by peer review”. As part of their COVID-19 response, the National Library of Medicine took the lead among database service providers and made the rather significant decision to index COVID-19 related preprints from specific preprint servers in PubMed, thereby enhancing their discoverability (and potential citations in new research) further.

That said – the debate about the benefits/challenges of preprints in the health sciences is still ongoing. However, it is becoming clear that preprints can no longer be ignored.

For a nice overview of where things stand with medRxiv (and other preprint servers) and where they may headed, be sure to check out the November 10, 2020 issue of JAMA, which includes these noteworthy papers:

Krumholz HM, Bloom T, Sever R, Rawlinson C, Inglis JR, Ross JS. Submissions and Downloads of Preprints in the First Year of medRxiv. JAMA. 2020;324(18):1903–1905. doi:10.1001/jama.2020.17529 

Flanagin A, Fontanarosa PB, Bauchner H. Preprints Involving Medical Research—Do the Benefits Outweigh the Challenges? JAMA. 2020;324(18):1840–1843. doi:10.1001/jama.2020.20674

Malički M, Jerončić A, ter Riet G, et al. Preprint Servers’ Policies, Submission Requirements, and Transparency in Reporting and Research Integrity Recommendations. JAMA. 2020;324(18):1901–1903. doi:10.1001/jama.2020.17195 

For more information on preprints – be sure to Ask Us at the MSK Library! 

Reflections on Advancing Authorship: Preprints in the Time of COVID-19

Posted on by

On Friday, September 25, 2020, the Library hosted our first ever virtual Advancing Authorship event, Preprints in the Time of COVID-19.

We heard from Dr. John Inglis of Cold Spring Laboratory, founder of preprint servers bioRxiv and medRxiv. We also heard from MSK authors about their decision to publish their COVID-19 related research as preprints, including Dr. Elizabeth Robilotti, Dr. Lior Braunstein, and Dr. Marin Hultcrantz. Overall, we had 149 attendees, and an engaging Q&A session. 

Screen Shot from “Preprints in the Time of COVID-19.”

If you attended, but didn’t have a chance to fill out our post-event survey, there’s still time!

Questions? Have an idea for a future Advancing Authorship event? Please contact asklibrarian@mskcc.org. 

 

 

 

Advancing Authorship Webinar: Preprints in the Time of COVID-19

Posted on by

Join us for the next event in our Advancing Authorship MSK Library Series: Preprints in the Time of COVID-19. 

During the COVID-19 pandemic, research has accelerated at an unprecedented pace and it has become more critical than ever for scientists to rapidly share their research results. Increasingly, researchers are relying on preprints to quickly communicate and share findings. In this session, we will explore the benefits and challenges of preprints. You’ll hear from MSK researchers who have published preprints on COVID-19, plus the Co-founder of two popular preprint servers, bioRxiv and medRxiv. 

Date: Friday, September 25
Time: 12:30 PM – 2:00 PM
Location: Zoom Webinar – REGISTER NOW

Speakers:

John Inglis, PhD – Dr Inglis is the Co-founder of bioRxiv and medRxiv, Cold Spring Harbor Laboratory’s preprint services for the life and health sciences.  He is also the founding Executive Director and Publisher of Cold Spring Harbor Laboratory Press in New York, a not-for-profit publisher of journals, books, and online media in molecular and cellular biology. He graduated from the University of Edinburgh Medical School with a PhD in immunology and was previously Assistant Editor of The Lancet, founding editor of Trends in Immunology, and managing editor of other Trends journals.  Follow John on Twitter @JohnRInglis.

Elizabeth Robilotti, MD, MPH, Dept. of Medicine, Associate Chief Medical Epidemiologist/Assistant Attending Infectious Diseases. Dr. Robilotti’s clinical practice directly influences her research in infection prevention and hospital epidemiology. She is focused on advancing the prevention of healthcare-associated infections  in high risk cancer patients through the application of molecular epidemiology. Through collaborations with the Microbiology Laboratory, Dr. Robilotti also works to refine new techniques  for more accurate and thorough surveillance and outbreak investigation. 

Lior Braunstein, MD, Dept. of Radiation Oncology, MSK – Board-certified radiation oncologist and scientist who specializes in treating breast cancer, prostate cancer, and primary and metastatic brain tumors. Dr. Braunstein has expertise in using advanced radiation therapy techniques, such as intensity-modulated radiation therapy, image-guided radiation therapy, stereotactic body radiation therapy, and stereotactic radiosurgery. His research is focused on molecular and biomarker-driven clinical trials, cancer epidemiology and outcomes analyses, and translational studies. As part of his clinical and scientific work, Dr. Braunstein serves on several national and international committees including the American Society of Clinical Oncology, the American Society for Radiation Oncology, and NRG Oncology, among others.

Malin Hultcrantz, MD, PhD, Dept. of Medicine, MSK – Hematologist with Clinical Expertise in Multiple Myeloma; Smoldering Myeloma; Monoclonal Gammopathy of Undetermined Significance (MGUS); Related Plasma Cell Disorders